share_log

Context Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Deep Track Capital, LP(9.89%),Deep Track Biotechnology Master Fund, Ltd.(9.89%), etc.

SEC announcement ·  May 10 16:07
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more